

Original Research Article

Title Page

Type of the manuscript: Original article

Title: A better perspective of nuclear atypia in Nottingham prognostic index: study on breast carcinoma patient cohort from Eastern India

Running title: Nuclear atypia in Nottingham prognostic index: breast carcinoma

Abstract

AIMS: This paper uses the parameter-based correlation to Nottingham prognostic index with specific attempt for histologic grade/ nuclear atypia.

PLACE AND DURATION OF THE STUDY: The retrospective analysis was conducted at Acharya Harihar Regional Cancer Research Centre and Hospital, Cuttack, Odisha within a period of 6 years starting from 2008 to 2013.

METHODOLOGY: In this paper we have done retrospective analysis of the histopathological data of 1372 breast carcinoma patients from eastern India and subjected to different regimens of therapy and patient health constitution driven treatment outcome. This paper uses the parameter-based correlation to NPI with specific attempt for histological grade/ nuclear atypia.

STATISTICAL METHOD: SPSS version 22. **RESULT:** The results of the study gives an impression that the correlation of NPI and histologic grade bears statistical significance and especially nuclear atypia and mitotic activity are two of those parameters with higher significance of correlation with NPI.

CONCLUSION: Nuclear atypia as seen from multivariate analysis and correlation study can be a better prognostic marker for a range of values with most the confidence interval being up to 3.71.

Keywords: Nuclear atypia; Histological Grade; Nottingham Prognostic Index; Breast cancer; Tumor Size; Nodal Involvement.

Introduction

Clinical management of breast cancer depends on various clinical and pathologic prognostic and predictive factors to support clinical and patient decision making for suitable treatment options. It has been largely accepted by the clinicians that there is no exact generalization of an effective breast cancer treatment. The common modalities of treatment involve surgery, radiotherapy, chemotherapy, hormone therapy and biological treatment [1]. A modern and effective approach has been adopting a combinatorial approach for treatment of breast cancer based on the clinicopathological parameters involved and patient history along with biomolecular signatures associated with the disease manifestation [2]. Therefore, it is imperative to identify and characterize the commonly associated parameters of breast cancer like type of breast cancer; size of tumor; stage of tumor; grade of tumor; whether the patient had menopause, general patient health constitution and the status of cancer cell sensitive to receptor targeted therapy (trastuzumab) [3,4]. Although

these parameters are mostly identified but the characterization along with correlation of these parameters with the most widely adopted prognostic index has been negligible in the scientific community leading to a broad prognostic score generation with limited applicability to treatment or early treatment options [5].

The Nottingham Prognostic Index (NPI), a continuous variable based index uses retrospective factors like tumor size [6], nodal involvement [7] and tumor histologic grade for determining the likelihood outcome of breast cancer patients [8]. NPI has been recognized as the only appropriately validated prognostic index in breast cancer [9]. The brief review of NPI gets clearer with the correlation summary of NPI scores and the predicated survival rates (Table 1). Higher the NPI score lower is the survival rate and higher is the aggressiveness of breast cancer.

Table 1: Correlation between NPI Scores and Survival rate

NPI Score	Survival rate (in %)
≥ 2.0 to ≤ 2.4	93
≥ 2.4 to ≤ 3.4	85
> 3.4 to ≤ 5.4	70
> 5.4	50

The prognostic index has not only facilitated stratification of treatment strategies but also has been linked with the typical and significant molecular changes involved in breast cancer. These molecular markers with stage specific expression patterns have been developed using immunohistochemistry method for different clinical samples of different stages of breast cancer (pre and post-surgery conditions) [10]. This improvised version of correlating the clinicopathological factors with that of the molecular markers involved in progression of breast cancer has led to the development of NPI-Plus (NPI+) [11,12]. In addition to predicting the treatment outcome and deciding for next course of treatment it also aids in sensitive modeling of treatment stage, patient health constitution and aggressiveness of cancer [13]. This bioinformatics modeling along with biological and clinical analysis has been the basis of improvised prognostic index development for breast cancer [14].

Understanding the clinic-pathological factors involved in breast cancer has aided the contemporary clinical management practices. One of the major outcomes of has been categorical identification of individual factors and their summative and independent correlation to prognostic index [15,16]. The three strongest prognostic determinants in operable breast cancer used in routine clinical practice internationally are lymph node (LN) stage, primary tumor size, and tumor histologic grade, which constitute Nottingham prognostic index [17,18]. In 1957, Bloom and Richardson proposed a simplified system, which utilized only three of Greenough's

variables: gland-formation (tubularity) degree of variation in nuclear size and shape (pleomorphism) [19], and 'hyperchromatic figures' as an estimate of proliferation to form the histological grade [20]. Though lymph node, which has traditionally been regarded as the most powerful prognostic factor in breast cancer, all the other factors are potentially regarded as prognostic factor.

The histologic grade of tumor is primarily determined by nuclear atypia (nuclear pleomorphism), nodal involvement and mitotic activity [21]. Broadly, the histologic grade for breast cancer range from: Grade 1 (Low grade)-> Grade 2 (Intermediate grade)-. Grade 3 (High grade) [22]. Cancers with lower grade profile tend to grow slowly and respond much efficiently to surgery and other treatment regimens (radiotherapy, chemotherapy, hormone therapy, biological treatments) [23]. This ensures higher survival rate, which thus can be deduced to be inversely related to NPI.

It is understood that the factors contributing to histologic grade have a correlation to the NPI. However, there has been no direct evidence of correlation of each of these factors or as independent parameters to NPI [24]. The Nottingham prognostic index, which has histologic grade as one of the constituting factors can be reasoned to have some significant and more indicative correlation to either of the factors making of histologic grade or a combination of those [25]. Nuclear atypia, nodal involvement and mitotic activity are three parameters making up the histologic grade [26,27] and more or less subjected to individual or contextual bias during observation or scoring [28,29]. However, the gap in this knowledge has limited our understanding and earlier prediction of treatment outcome or more clearly poorer prognosis.

This paper tries to identify the correlation of the factors making up histologic grade of tumors to that of the calculated Nottingham prognostic score [30,31]. The long-term aim of the work is to establish a better perspective to these factors other than mere calculation of histologic grade [32] and thereby develop any such significant factor for early prognosis in cases of breast carcinomas.

Methods

Patient Selection:

The samples were collected from 1372 primary invasive breast cancer patients for a period of 6 years starting from 2008 to 2013 from Acharya Harihar Regional Cancer Research Centre and Hospital, Cuttack, Odisha. A series of histopathological analysis and data collection was subsequently followed up. The histopathological data was subjected to univariate, multivariate and parametric statistical analysis using IBM SPSS software version 22 (SPSS Inc., Chicago, IL, USA) [33,34].

The age of patients considered for the study ranged from 20 to 82 (Fig.1) years old of which most were subjected to surgery/radiotherapy/chemotherapy and/or a suitable combination of these treatment options. The detailed patient characteristics and the parameter range used for this study has been summarized in Table 2. The

sample processing involved initial clinical review of formalin fixed histological sections embedded with paraffin. This study was conducted under the regulations of Indian council of medical research. The handling of biological specimens from tumor banks, being the samples available for research and clinical purposes in retrospective studies.

136

The histological diagnoses were cross-verified by trained pathologists. The tumor samples were categorical characterized for parameters like tumor size, nodal status, histologic grade, surgical margin, nuclear atypia, mitotic activity, (Table 2). In samples with valid data for all the parameters, NPI was calculated using the standard equation:

142

143

$$\text{NPI} = 0.2 \times \text{tumor size (cm)} + \text{grade (1-3)} + \text{lymph node status (1-3)}$$

144

In addition, patient history and medical related information were collected like age, sex, spread of breast cancer and their geographical origin (broadly defined in this paper as belonging to eastern India). Tumor size, histologic grade and the corresponding NPI are most frequent for their respective median values. The most frequent tumor size was 2-5 cm (86.7%) with the mean being 3.83 cm $\pm$ 2.00 cm (Fig.1). Similarly, histologic grade of tumors was mostly reported for grade 2 tumors (60%) indicating moderately severe aggressiveness of tumors among the cohort of patients.

The calculated NPI was most frequent for the range “3.4 $\leq$ NPI $\leq$ 5.4 and NPI > 5.4” (Fig.1) indicating intermediate to poor survivability rates post treatment of the patients under consideration. With reference to the standard correlation of NPI with survivability rates (Table 1) it is assumed to be between 50-70% for the patient cohort under focus.

158

159

Table 2 showing patient characteristics and tumour parameters

Variable (N = 1372)	Data
Age at Diagnosis, years	
Mean and standard deviation	47.06 $\pm$ 10.714
Range	62 (Min 20; Max 82)
Tumor Size (cm)	
Mean and standard deviation	3.83 cm $\pm$ 2.00 cm
Range	16.2 (Min 0.8; max 17)
T1: < 2 cm	94 (7.67%)

T2: 2-5 cm	1092 (86.7%)
T3: > 5 cm	469 (38.3%)
Not assessed	148
Lymph Node Invasion	
Present	657 (48.59%)
Absent	695 (51.40%)
Not assessed	20
Histological Grade	
Grade I	33 (2.50%)
Grade II	767 (60.10%)
Grade III	471 (37.0%)
Not assessed	101
Nottingham Prognostic Index	
NPI < 3.4	50 (4.14%)
$3.4 \leq \text{NPI} \leq 5.4$	566 (46.90 %)
NPI > 5.4	589 (48.80%)


160

161 **Statistical analysis:**

162 The histological data collected from the 1372 breast cancer patients was subjected
163 to statistical analysis using IBM SPSS software version 22.0 (SPSS Inc., Chicago, IL,
164 USA). The convention used in the data representation (Table 2) is: continuous
165 variables have been represented in form of mean standard deviation and category-
166 based variables have been represented as percentages.

167 The data was subjected to distribution analysis to ensure comparison uniformity
168 among different parameters being used in this study, namely NPI; histologic grade;
169 nuclear atypia; mitotic activity; nodal involvement and tumor size. An unpaired T-
170 test with 95% confidence interval was used for generating the mean differences for
171 continuous variables. The above specified parameters were subjected to univariate,
172 multivariate and parameter bias analysis using SPSS. In addition to develop a
173 predictive model for determining the range of NPI that can be predicted with the
174 constituent factors making up histologic grade we performed a predictive analysis
175 where the scores with 95% confidence was considered significant for our study. In
176 this paper we have used Pearson correlation and chi-squared tests to determine the
177 associativity of the parameters with NPI. (fig1)

178
179



180

181 Fig.1. Distribution of the patient characteristics involved in the study of correlation
182 of histologic grade parameters with NPI in 1372 breast cancer patients.

183

184 **Result**

185

186 1. **Correlational Analysis:** The study focuses on understanding the correlation of the
187 Nottingham prognostic index (NPI) along with that of histologic grade as well as the
188 factors contributing to it. However, the approach to deduce the correlation of the
189 factors making up histologic grade independently to that of NPI has been an unique
190 and over searching attempt of this paper to understand for any clinical/ biological
191 parameter that holds significant correlation to NPI and thus can be developed as an
192 aid for early prognosis of breast cancer prior to standardization of NPI scores. The
193 parameters giving rise to NPI like tumor size, lymph node involvement and histologic
194 grade have also been attempted for finding any intuitive correlation. For the purpose
195 of higher accuracy we have adopted the significance threshold to be at 0.01 level (2-
196 tailed).

197

198 Of the parameters making up histologic grade only nuclear atypia and mitotic activity
199 hold significantly high correlation (0.079 and 0.076 respectively) with that of NPI in

contrast to tubule formation (Table-3). Thus, we build on our hypothesis that among three factors contributing to histologic grade, mitotic activity and nuclear atypia hold stronger correlation and thus can be potential candidate for independent early prediction of treatment outcome in breast cancer patients. This correlational analysis or associativity study helps to build a more objective hypothesis that nuclear atypia or mitotic activity can be a better prognostic marker in contrast to tubule formation. In addition, the positively significant correlation also establishes a retrospective link of “not just histologic grade but factors making histologic grade can be better prognostic markers”. This adds higher prognostic power to the less explored parameters like nuclear atypia and mitotic activity.

Table 3: Correlation Analysis of NPI with that of its constituent parameters (tumour size, nodal involvement and histologic grade)

Correlations							
	PROGNOSTIC SCORE	T. SIZE	TUBULE FORMATION	NUCLEAR ATYPIA	MITOTIC ACTIVITY	Computed node	HISTOLOGIC GRADE
PROGNOSTIC SCORE	1	.022	.007	.076	.079	.034	.079
		.456	.819	.009	.006	.234	.006
	1202	1147	1184	1185	1184	1200	1185

**. Correlation is significant at the 0.01 level (2-tailed).

*. Correlation is significant at the 0.05 level (2-tailed).

215
216





2. Sample distribution study and range homogenization:

217
218

Considering the ample number of sample, i.e. 1372 samples from eastern Indian cohort of patients, it is imperative to understand that the difference in sample exposure to climate, genetic make-up, epigenetic influencers as well as the experimental bias do not significantly mask the correlation outcome. So, it was hypothesized that identification of the frequency distribution patterns (Fig2) and the correlation of the various categories with that of histologic grade and the parameter of focus i.e. “nuclear atypia” will enable us to confirm the applicability of our data to clinical set up and to homogenize the differential missing data for each parameters among all the samples.


228
229

Frequencies w.r.t Histologic Grade (SBR)



(a)

230
231



(b)

Fig.2: (a) and (b): Frequency distribution of breast cancer parameters like NPI, Tumour size, tubule formation, mitotic activity and nodal involvement with that of histologic grade/nuclear atypia.


The NPI as well as the inherent factors like tumor size and nodal involvement have a similar pattern of distribution with the most of the samples being crowded around the median case for each. With respect to histologic grade there is a significant mismatch of the range of sample distribution of NPI and histologic grade where

242 histologic grade is mostly accumulate within grade I and grade II tumors. So the
243 applicability of NPI for prognosis forecasting might lead to erroneous assumption
244 and clinical bias during treatment.

245 However, nuclear atypia has a much similar frequency distribution pattern in
246 comparison to NPI as well as other parameters like tumor size, nodal involvement
247 and tubule formation.

248
249
250

3. Histologic grade and the role of contributing parameters:



251
252

253 Fig.3. Frequency distribution of breast cancer parameters like NPI, Tumor size,
254 tubule formation, mitotic activity and nodal involvement with that of histologic
255 grade/nuclear atypia.

256

257 Histologic grade of tumors is the summation of three parameters observed in tumors
258 like nuclear atypia, tubule formation and mitotic activity. As deciphered from the
259 correlation analysis (Table 3) nuclear atypia and mitotic activity have higher
260 significance and independent correlation to that of NPI and thus characterizing the
261 pattern of this categorical variable for the continuous variable (NPI) is important to
262 deduce a meaningful relationship.

263

264 Nuclear atypia and mitotic activity as like NPI also hold their most frequent
265 observation in the median range, which means a case of intermediate nuclear
266 pleomorphism or atypia and mitosis. This suggests that nuclear atypia or mitotic
267 activity or both can have a stronger predictive correlation depending how significant
268 is their univariate/ multivariate analysis.

269

4. Univariate Analysis:

270

271 Univariate analysis with NPI as the dependent variable subjected to parametric
272 variations highlight histologic grade to the better prognostic marker in comparison
273

to other parameter like nuclear atypia, tubule formation and mitotic activity (Table 4). NPI has a high significant correlation with histologic grade 0.864 in comparison to nuclear atypia (0.421) and tubule formation (0.439). The result of univariate analysis supports the contemporary convention that the “histologic grade itself can be an early prognostic factor than that of inherent factors like nuclear atypia and mitotic activity”. However, modeling the prognostic index using univariate analysis limits the variability of the multiple parameters and doesn't resemble or recreate the practical influence of multiple parameters on NPI. Therefore, we proceed with multivariate analysis.

Table 4: Univariate correlation analysis of NPI with that of its constituent parameters (tumour size, nodal involvement, histologic grade, nuclear atypia and mitotic activity)

Tests of Between-Subject Effects Dependent Variable: Prognostic Score		
Source	Mean Square	Sig.
TUBULE FORMATION	108.141	0.439
NUCLEAR ATYPIA	310.858	0.421
MITOTIC ACTIVITY	32.491	0.190
T.SIZE	5.312	0.671
HISTOLOGIC GRADE		0.864
Computed Node	242.327	0.234

**Correlation is significant at the 0.01 level (2-tailed)

5. Multivariate Analysis:

Table 5: Multivariate analysis of NPI, tumour size, nodal involvement, mitotic activity and tubule formation with that of histologic grade and nuclear atypia

Parameter Estimates					
Dependent Variable	Parameter	Std. Error	Sig.	95% Confidence Interval	
				Lower Bound	Upper Bound
PROGNOSTIC SCORE	Intercept	2.760	.878	-5.839	4.991
	HISTOLOGICGRADE	1.398	.337	-1.401	4.085
	NUCLEARATYPIA	1.454	.555	-1.995	3.711
T. SIZE	Intercept	.319	.000	2.377	3.627
	HISTOLOGICGRADE	.161	.004	.145	.778
	NUCLEARATYPIA	.168	.617	-.413	.245
Computed node	Intercept	1.217	.005	1.034	5.808
	HISTOLOGICGRADE	.604	.248	-.487	1.882
	NUCLEARATYPIA	.634	.849	-1.365	1.123
MITOTIC ACTIVITY	Intercept	.083	.000	.844	1.171
	HISTOLOGICGRADE	.042	.000	.843	1.008
	NUCLEARATYPIA	.044	.000	-.407	-.235
TUBULE FORMATION	Intercept	.118	.000	1.822	2.286
	HISTOLOGICGRADE	.060	.000	-.494	-.259
	NUCLEARATYPIA	.062	.013	.033	.277

**Correlation is significant at the 0.01 level (2-tailed).

297
 298 A multivariate analysis of NPI with that of histologic grade and nuclear atypia reveals
 299 a contradictory or more suggestive explanation to the univariate analysis result
 300 (Table 5). Here nuclear atypia is more significantly related to NPI score than that of
 301 histologic grade but the confidence interval for histologic grade runs higher than that
 302 for nuclear atypia. Nuclear atypia for the sample of this study mostly range in the
 303 intermediate range (Fig.3) therefore a confidence threshold of 3.711 permits only
 304 type 1 and type 2 cases of nuclear atypia. However, histologic grade with confidence
 305 threshold of 4.095 accounts for most of the reported tumor grades, which range
 306 among grade 1/2/3 and most frequently in this study for grade 2. Thus, in a way
 307 histologic tumor grade has a wider window for accommodating higher number and
 308 variety of samples for better prognosis for most of the breast cancer patients
 309 whereas nuclear atypia, is limited by the specific confidence limit for up to 3.711.

310 311 **6. Non-Parametric Analysis:**

312
 313 **Table 6: Non-parametric analysis of NPI, histologic grade and nuclear atypia using**
 314 **Friedman's Two-way Analysis of variance by ranks**

Hypothesis Test Summary			
	Null Hypothesis	Test	Sig.
1	The distributions of PROGNOSTIC SCORE, T. SIZE and HISTOLOGIC GRADE are the same.	Related-Samples Friedman's Two-Way Analysis of Variance by Ranks	.000
			Reject the null hypothesis.


Asymptotic significances are displayed. The significance level is .05.

315
 316
 317 In order to account for and eliminate the bias of any parameter towards NPI and the
 318 model of multivariate analysis with NPI as the dependent variable and histologic
 319 grade and nuclear atypia as the parameters is subjected to Friedman's Two-way
 320 analysis of variance by ranks. The result indicates that no significant parametric bias
 321 exists in the multivariate analysis model used above (Table 5) and thus the null
 322 hypothesis, i.e. "NPI, Tumor Size and Histologic grade" are the same for nuclear
 323 atypia stands rejected.

324 325 **7. Predictive analysis of NPI w.r.t to histologic grade/ nuclear atypia.**

326
 327 The correlational analysis and variable study of NPI with that of histologic grade and
 328 nuclear atypia suggests for possible methods for early prognosis of breast cancer
 329 from clinical data. Therefore, modeling in retrospective manner will help to generate
 330 a predictive model for estimating the treatment outcome of patient and thereby
 331 deciding how reliable can the nuclear atypia based prognosis can be in face of the
 332 95% confidence interval being exerted upon.

333
 334 The confidence co-efficient (CCF) of NPI with respect to histologic tumor grade and
 335 nuclear atypia help in a developing a reference based model for predicting the
 336 treatment outcome. The model as shown in Fig.4 represents the table of NPI
 337 correlation to histologic grade or nuclear atypia and the reliability of the prediction
 338 using 95% confidence interval as the filter.
 339



340 Fig.4. Predictive analysis model of NPI using histologic grade/ nuclear atypia as
 341 significant parameter estimates.
 342

343 Discussion

344
 345 The Nottingham prognostic index has been the most widely accepted and used
 346 prognosis index for primary operable breast cancers around the world. Several
 347 experimental data arising from different geographical coordinates of the world have
 348 confirmed the validity of NPI and simultaneously few of these have added
 349 exceptions or newer possibilities to the NPI. In this paper, we tried to understand
 350 how histologic grade (considered to be an independent prognostic parameter in
 351 comparison to tumor size and node status) correlates to NPI. Precisely, we have
 352 explored the patterns of possible correlation of parameters making up histologic
 353 tumor grade and NPI.
 354

From the correlational analysis the results gave a clear indication that indeed the correlation of NPI and histologic grade bears statistical significance and especially nuclear atypia and mitotic activity (factors constituting histologic grade) are two of those parameters with higher significance of correlation with NPI. Further since the data set for the study consisted to heterogeneous valid data for each parameters, it was necessary to compare the distribution and frequency of the parameters including NPI to eliminate experimental error and input / output mismatch. The data of 1372 breast cancer patients suggested that most of the data remained in the median distribution range and the nature of tumor under study ranged from intermediate to severely aggressive ones with lesser survivability rates and poorer treatment outcomes.

Associativity analysis using univariate and multivariate analysis models suggest that nuclear atypia than the overall histologic grade holds significance in early and better prognosis of breast cancer patients but the confidence levels with which NPI can be predicted using either of these as parameters varies. Histologic grade has a wide range of grade values for which NPI can be predicted with more than 95% confidence score whereas nuclear atypia experiences a lower threshold cut-off at just 3.711 for predicting NPI. This suggests practical limitation of nuclear atypia in predicting prognosis for intermediate and severely aggressive breast cancers where the survival rates are low. In other words, nuclear atypia as an independent prognostic marker serves good when used for predicting grade 1/ grade 2 tumors with NPI ranging 5.4 or less. Since, most of the cases of less aggressive breast cancers are hard to detect and less reported the clinical appreciation of nuclear atypia, as an important prognostic factor has been less. In addition the non-parametric analysis suggested there is no statistical parametric based bias as nuclear atypia recognizes NPI, tumor size and histologic grade to be independent parameters and correlates differentially with each of these.

Future Perspective

It would be expected in the scientific and clinical domain that any prognostic tool developed must be applicable to all the known forms of breast carcinomas. However, one of the major limitations to developing NPI is the inability or the paradoxical applicability to triple negative breast cancer patients (insensitive to estrogen, progesterone and trastuzumab targeted therapy).

The existing results of triple negative breast cancer suggest that there is a prevalence of lymph node metastasis at the time of diagnosis. In contradiction few other literatures suggest that the metastasis and spread of cancer cells in triple negative breast cancer have a heterogeneous preference and doesn't always spread to lymph nodes. Breast cancer in general is characterized by heterogeneity of patient outcome in terms of response to treatment and their health constitution. However, this heterogeneity is further complicated in triple negative breast cancer patients.

Conclusion

401 A future perspective of developing NPI is to identify and characterize the prognostic
402 patterns associated with triple negative breast cancers and specifically characterize
403 for cases with lymph node metastasis and those without. This retrospective analysis
404 will allow for a more widely accepted form of NPI with better applicability to triple
405 negative breast cancer patients.

406

407

408 **Ethical approval**

409 Not applicable

410

411 **Conflict of interests**

412 Authors declared that no conflict of interests exists.

413

414 **Consent**

415 Not applicable

416

417

418 **References:**

419

420 1. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer: A
421 study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer
422 11:359-377, 1957.

423

424 2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I: The value of
425 histological grade in breast cancer: Experience from a large study with long-term
426 follow-up. Histopathology 19:403-410, 1991.

427

428 3. Symmers WC. Assessment of Histological Grade. Edinburgh, United Kingdom,
429 Churchill Livingstone, 1998.

430

431 4. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al.
432 Pathological prognostic factors in breast cancer. IV: Should you be a typer or a
433 grader? A comparative study of two histological prognostic features in operable
434 breast carcinoma. Histopathology 27:219-226, 1995.

435

436 5. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B. Applying the Nottingham
437 Prognostic Index to a Swedish breast cancer population: South East Swedish Breast
438 Cancer Study Group. Breast Cancer Res Treat 53:1-8, 1999.

439

440 6. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: A
441 reproducibility study. Cancer 73:2765-2770, 1994.

442

443 7. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC et
444 al. Interobserver reproducibility of the Nottingham modification of the Bloom and
445 Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J
446 Clin Pathol 103:195-198, 1995.

447

- 448 8. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological
449 grading of breast carcinomas: A study of interobserver agreement. *Hum*
450 *Pathol*26:873-879, 1995.
451
- 452 9. Walker RA. Prognostic and Predictive Factors in Breast Cancer (ed 1). New York,
453 NY, Informa Health Care, 2003.
454
- 455 10. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in
456 primary breast cancer. *Breast Cancer Res Treat* 22:207-219, 1992.
457
- 458 11. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. *Crit*
459 *Rev Oncol Hematol*31:209-223, 1999.
460
- 461 12. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The
462 Nottingham Prognostic Index applied to 9,149 patients from the studies of the
463 Danish Breast Cancer Cooperative Group (DBCG). *Breast Cancer Res Treat* 32:281-
464 290, 1994.
465
- 466 13. D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in
467 breast cancer: The predictive value of the Nottingham Prognostic Index in patients
468 with a long-term follow-up that were treated in a single institution. *Eur J Cancer*
469 37:591-596, 2001.
470
- 471 14. Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Yamada M, Tanaka K, et al.
472 Prognostic factors in breast cancer: The value of the Nottingham Prognostic Index
473 for patients treated in a single institution. *Surg Today* 35:907-911, 2005.
474
- 475 15. Clark GM. Do we really need prognostic factors for breast cancer? *Breast Cancer*
476 *Res Treat* 30:117-126, 1994.
477
- 478 16. Anttinen J, Kautiainen H, Kuopio T. Role of mammography screening as a
479 predictor of survival in postmenopausal breast cancer patients. *Br J Cancer* 94:147-
480 151, 2006.
481
- 482 17. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection
483 method in predicting breast cancer survival: Analysis of randomized screening
484 trials. *J Natl Cancer Inst*97:1195-1203, 2005.
485
- 486 18. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and
487 management of patients with node-negative invasive breast carcinoma that is 1 cm
488 or smaller in size (stage 1; T1a,bN0M0): A review of the literature. *J*
489 *Clin Oncol*24:2113-2122, 2006.
490
- 491 19. NHS Breast Screening Programme: Guidelines for Pathology Reporting in Breast
492 Cancer Screening and the Second Edition of The Royal College of Pathologists'
493 Minimum Dataset for Breast Cancer Histopathology. Sheffield, United Kingdom,
494 NHS, 2005.

495
496 20.European Commission: European Guidelines for Quality Assurance in
497 Mammography Screening. Luxembourg: Office for Official Publications of the
498 European Communities 1996.
499
500 21.WHO: Classification of Tumours: Pathology and Genetics. Lyon, France, IARC
501 Press, 2003.
502
503 22.Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al. Prognostic
504 factors in breast cancer: College of American Pathologists Consensus Statement
505 1999. Arch Pathol Lab Med 124:966-978, 2000.
506
507 23.Singletery SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of
508 the American Joint Committee on Cancer staging system for breast cancer. J
509 Clin Oncol 20:3628-3636, 2002.
510
511 24.Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, et al. Comparison
512 of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological
513 grades in a series of 825 cases of breast cancer: Major importance of the mitotic
514 count as a component of both grading systems. Anticancer Res 18:571-576, 1998.
515
516 25.Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JF, Blamey RW. The prognosis
517 of small primary breast cancers. Eur J Cancer 35:908-912, 1999.
518
519 26.Rosner D, Lane WW. Should all patients with node-negative breast cancer receive
520 adjuvant therapy? Identifying additional subsets of low-risk patients who are highly
521 curable by surgery alone. Cancer 68:1482-1494, 1991.
522
523 27.Yu K, Lee CH, Tan PH, Hong GS, Wee SB, Wong CY, et al. A molecular signature of
524 the Nottingham prognostic index in breast cancer. Cancer Res 64:2962-2968, 2004.
525
526 28.Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J et al. Genetic
527 reclassification of histologic grade delineates new clinical subtypes of breast
528 cancer. Cancer Res 66:10292-10301, 2006.
529
530 29.Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression
531 profiling in breast cancer: Understanding the molecular basis of histologic grade to
532 improve prognosis. J Natl Cancer Inst 98:262-272, 2006.
533
534 30.Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM et
535 al. Interobserver reproducibility of histopathological features in stage II breast
536 cancer: An ECOG study. Breast Cancer Res Treat 5:3-10, 1985.
537
538 31.Elston CW. The assessment of histological differentiation in breast cancer. Aust N
539 Z J Surg 54:11-15, 1984.
540
541 32.Theissig F, Kunze KD, Haroske G, Meyer W. Histological grading of breast cancer:

542 Interobserver, reproducibility and prognostic significance. *Pathol Res Pract* 186:732-
543 736, 1990.
544
545 33. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, et al. Impact of a
546 national external quality assessment scheme for breast pathology in the UK. *J*
547 *Clin Pathol* 59:138-145, 2006.
548
549 34. Sundquist M, Mitchell M, Blamey R, Blichert-Toft M, Cataliotti L, Holli K, et al. The
550 prognosis of small breast cancers and selection for omission of adjuvant
551 chemotherapy. *Eur J Cancer* 5:14-15, 2007.